Lamotrigine, Mexiletine Show Similar Benefits for Nondystrophic Myotonias
By Lori Solomon HealthDay Reporter
WEDNESDAY, Oct. 9, 2024 -- Improvements in nondystrophic myotonias symptoms are similar for lamotrigine and mexiletine, according to a study published in the October issue of The Lancet Neurology.
Vinojini Vivekanandam, Ph.D., from the Centre for Neuromuscular Disorders at the National Hospital for Neurology and Neurosurgery in London, and colleagues randomly assigned 53 adults with genetically confirmed symptomatic nondystrophic myotonia to receive either mexiletine for eight weeks followed by lamotrigine for eight weeks or lamotrigine followed by mexiletine with a seven-day washout period in between.
The researchers found that the mean interactive voice response stiffness score after treatment with mexiletine was 2.54 versus 2.77 with lamotrigine (mean mexiletine-lamotrigine difference, −0.23; 95 percent confidence interval, −0.63 to 0.17). For both groups, the most common adverse event was indigestion-reflux (eight participants, 208 participant-days receiving mexiletine; seven participants, 130 participant-days receiving lamotrigine). There were no serious adverse events.
"Approximately one in 17 people in the U.K. have a rare disease and the majority have no treatment. Many are neurological diseases and rarity makes clinical trials to develop treatments very difficult," Vivekanandam said in a statement. "The trial results are very exciting and important for patients with this muscle channelopathy."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-10-10 06:00
Read more
- E. Coli Fears Spur Recall of 167,000 Pounds of Ground Beef
- Lower Risk for Asthma Seen With Younger Age at Natural Menopause
- Low Zinc Levels Seen With Liver Cirrhosis, Hepatic Encephalopathy
- COVID Vaccine Mistrust Levels Aren't Budging, Study Finds
- Clinical Practice Guideline Updated for Migraine, Tension-Type Headache
- Overtreatment of Prostate Cancer Increasing in Men With Short Life Expectancy
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions